Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22778814 | 0.92 | MAPT (0.51) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL17731974 | 0.86 | MAPT (0.59) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL17731972 | 0.85 | MEN1 (0.53) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL27101116 | 0.85 | MEN1 (0.55) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL17731916 | 0.84 | MEN1 (0.53) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL17731873 | 0.84 | MEN1 (0.66) | MAPTTP53MAPK1MEN1KMT2A | |
| SCHEMBL17732015 | 0.83 | RAB9A (0.60) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL17731985 | 0.83 | NPC1 (0.63) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL17731936 | 0.83 | MAPT (0.55) | MAPTTP53POLBMAPK1MEN1 | |
| SCHEMBL17732035 | 0.81 | MAPT (0.52) | MAPTTP53POLBMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIV KANSAS (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIV KANSAS (US) | 2022-12-15 | — | — | US | disclosed |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | UNIVERSITY OF KANSAS (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | UNIVERSITY OF KANSAS (US) | 2020-12-15 | — | — | US | disclosed |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS | 2018-10-04 | — | — | US | disclosed |
| EP-3215152-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | The University of Kansas (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073633-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073633-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | MAPT 260/4885TP53 503/4885POLB 828/4885 |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | MAPT 260/4885TP53 503/4885POLB 828/4885 |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | MAPT 260/4885TP53 503/4885POLB 828/4885 |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | MTCH2, TIMM50, TIMM10 | MAPT 260/4885TP53 503/4885POLB 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.